Belite Bio, Inc

NasdaqCM:BLTE 株式レポート

時価総額:US$2.3b

Belite Bio マネジメント

マネジメント 基準チェック /24

Belite Bioの CEO はTom Linで、 Nov2021年に任命され、 の在任期間は 6.67年です。 は、会社の株式の1.72%を直接所有しており、その価値は$ 40.06M 。経営陣と取締役会の平均在任期間はそれぞれ3年と3年です。

主要情報

Tom Lin

最高経営責任者

n/a

報酬総額

CEO給与比率n/a
CEO在任期間3yrs
CEOの所有権1.7%
経営陣の平均在職期間3yrs
取締役会の平均在任期間3yrs

経営陣の近況

Recent updates

We're Interested To See How Belite Bio (NASDAQ:BLTE) Uses Its Cash Hoard To Grow

Sep 26
We're Interested To See How Belite Bio (NASDAQ:BLTE) Uses Its Cash Hoard To Grow

Are Investors Undervaluing Belite Bio, Inc (NASDAQ:BLTE) By 45%?

Jul 03
Are Investors Undervaluing Belite Bio, Inc (NASDAQ:BLTE) By 45%?

We're Hopeful That Belite Bio (NASDAQ:BLTE) Will Use Its Cash Wisely

Mar 20
We're Hopeful That Belite Bio (NASDAQ:BLTE) Will Use Its Cash Wisely

An Intrinsic Calculation For Belite Bio, Inc (NASDAQ:BLTE) Suggests It's 49% Undervalued

Jan 10
An Intrinsic Calculation For Belite Bio, Inc (NASDAQ:BLTE) Suggests It's 49% Undervalued

Belite Bio, Inc's (NASDAQ:BLTE) Intrinsic Value Is Potentially 25% Below Its Share Price

Jul 31
Belite Bio, Inc's (NASDAQ:BLTE) Intrinsic Value Is Potentially 25% Below Its Share Price

We're Not Worried About Belite Bio's (NASDAQ:BLTE) Cash Burn

May 03
We're Not Worried About Belite Bio's (NASDAQ:BLTE) Cash Burn

Belite Bio down 21% after disappointing mid-stage results of rare eye disease candidate

Oct 03

Belite Bio receives approval of begin LBS-008 phase 3 trial in China

Sep 16

Belite Bio adds 15% as pivotal trial for lead asset starts in U.S.

Aug 22

Belite Bio GAAP EPS of -$0.23 beats by $0.05

Aug 12

Belite Bio (NASDAQ:BLTE) Is In A Good Position To Deliver On Growth Plans

Aug 01
Belite Bio (NASDAQ:BLTE) Is In A Good Position To Deliver On Growth Plans

Belite seeks FDA nod to proceed with phase 3 trial of genetic eye disease treatment

Jul 19

CEO(最高経営責任者

Tom Lin (45 yo)

3yrs

在職期間

Dr. Yu-Hsin Lin, also known as Tom, MBA MMed PhD (Med) is the founder and has served as Director of Belite Bio Inc since March 2018 and its Chairman and served as the Chief Executive Officer since November...


リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Yu-Hsin Lin
Chairman of the Board of Directors & CEO3yrsデータなし1.72%
$ 40.1m
Hao-Yuan Chuang
CFO & Director4.6yrsデータなし1.01%
$ 23.5m
Nathan Mata
Chief Scientific Officer3yrsデータなしデータなし
Hendrik Scholl
Chief Medical Officer & Member of Ophthalmology Clinical Advisory Boardless than a yearデータなしデータなし

3.0yrs

平均在職期間

45yo

平均年齢

経験豊富な経営陣: BLTEの経営陣は 経験豊富 であると考えられます ( 3年の平均在職年数)。


取締役

名称ポジション在職期間報酬所有権
Yu-Hsin Lin
Chairman of the Board of Directors & CEO6.7yrsデータなし1.72%
$ 40.1m
Hao-Yuan Chuang
CFO & Director3yrsデータなし1.01%
$ 23.5m
Hendrik Scholl
Chief Medical Officer & Member of Ophthalmology Clinical Advisory Boardno dataデータなしデータなし
Frank Holz
Member of Ophthalmology Clinical Advisory Boardno dataデータなしデータなし
Yuan Lu
Independent Director2.6yrsデータなしデータなし
Quan Dong Nguyen
Member of Ophthalmology Clinical Advisory Boardno dataデータなしデータなし
Michel Michaelides
Member of Ophthalmology Clinical Advisory Boardno dataデータなしデータなし
Wan-Shan Chen
Director3yrsデータなしデータなし
Hung-Wei Chen
Director3yrsデータなしデータなし
John Longo
Independent Director2.6yrsデータなしデータなし
Gary Biddle
Independent Director2.6yrsデータなしデータなし
Robyn Guymer
Member of Ophthalmology Clinical Advisory Boardno dataデータなしデータなし

3.0yrs

平均在職期間

45yo

平均年齢

経験豊富なボード: BLTEの 取締役会経験豊富 であると考えられます ( 3年の平均在任期間)。